News
The heart of the matter: How CordiFio is creating change
FemTech World speaks to Petronela Sandulache of CorDiFio about why heart condition diagnoses are harder for women
Heart health for women can be a difficult diagnosis to make due to symptoms mirroring other conditions. FemTech World meets Petronela Sandulache founder of CorDiFio
Petronela started her career in the consulting and automotive industry all over the world before a family tragedy made her assess her goals.
She said: “When something terrible happened in my family, it made me think about life and what it is all about. The most important person in our lives had a misdiagnosis and that was it. Someone who is relatively healthy just disappears overnight. That was when I started to investigate the disparities in medical diagnosis for women.”
Petronella added: “Women present different types of symptoms that get confused with indigestion or anxiety rather than being taken seriously and having a further investigation. Once I started investigating, I found out that the number one killer of women more than all cancers combined is heart disease yet 50 per cent following an attack get misdiagnosed.
This is huge pressure on the healthcare system because misdiagnosis means wrong treatments and doctors. The ones who are paying the price are women.”

Heart attacks and health
When it comes to heart attacks, women present different symptoms to men. Yet when it comes to diagnosis, the male symptoms are often used as a benchmark for how it presents.
Petronela explained: “In research conducted by the Canadian stroke and heart foundation, they discovered that 30 to 50 per cent of women diagnosed with depression are actually misdiagnosed and this can mask heart disease in women. They have only recently started to investigate the problem of heart disease, stroke or Alzheimer’s disease in women and why things present differently.”
Hormones are one reason why women have been excluded from studies and it’s why certain conditions present differently in women. Women also face challenges when it comes to taking part in clinical trials such as childcare or pregnancy.
“Obviously we have hormones that are not taken into consideration when you just study male models. So I thought we need to do something about this because femtech is just about tracking your period, making babies or menopause. Women are much more than their reproductive organs. Everything we know about common diseases, treatments and diagnosis has been done on men,” Petronela said.
“We need to do something about heart disease because if you don’t know that you have it, then you can be gone in five minutes. That’s why I called the company, CorDiFio, it means, in Italian, the heart of Fio which was the name of my mother. I’m dedicating this to her and all the women out there so they don’t need to go through the same type of thing,” she added.
The research also revealed that different ethnic backgrounds may place women at higher risks for cardiovascular diseases.
Petronela said: “It’s important to note within the female population, we have ethnic backgrounds with different risk profiles. We know that African, Hispanic or southeast Asian women have a higher probability of dying from cardiovascular disease compared to caucasian women.”
Heart health awareness
CorDioFio is dedicated to raising awareness so that women can detect heart problems early before it becomes a medical emergency. Its goal is to empower both women and their doctors to come up with early detection which will help to save lives.
“The great news is that 80 per cent of heart disease and strokes are preventable if caught in time. We are determined to keep women’s hearts beating longer.”
When it comes to CorDiFio’s technology, how does it work for patients?
Petronella explained: “If you download our app or go to the website to register then we take you on a journey by asking specific questions that take about 20 minutes to answer. We will generate a personalised health report for you to download and take to your appointment with your GP. You will learn your risk factors, where you need to keep an eye out and it’s something tangible to start that conversation with doctors by highlighting things you wouldn’t have thought of.”
She added: “We have tested this with various women from all over the world to see what their doctors say about the reports. They found that they don’t have a heart problem which is great so it’s peace of mind but some found they had other issues which present a diagnostic opportunity. We want to integrate this and are working with wearables.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Fertility2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






